Earnings Call · Q3 FY2021·2021-08-06

Q3 21EPS -100.00%*·Rev n/aQ2 21EPS -52.94%·Rev n/aQ1 21EPS +16.67%·Rev n/aQ4 20EPS -100.00%*·Rev n/a⚠ consensus missing

ARROWHEAD PHARMACEUTICALS, INC. ARWR

Vincent Anzalone — Conference Call Host, likely Investor Relations or Communications

Christopher Anzalone — President and CEO

Javier San Martin — Management, clinical development or medical affairs

Ken Myszkowski — Management, likely Chief Financial Officer or Finance Executive

−4.8%1d on move date−5.0% vs SPY3d−10.1%5d−12.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARWR calls or request research access.

More ARWR calls Browse calls Request research access